Literature DB >> 12920154

Pheochromocytoma: state-of-the-art and future prospects.

Emmanuel L Bravo1, Rodrigo Tagle.   

Abstract

This review provides current understanding of the pathophysiology of pheochromocytoma and the wide range of associated clinical manifestations that have led to earlier recognition of the disease. In addition, it reviews optimal screening methods and localization techniques that have enhanced the clinician's ability to make the diagnosis with greater certainty. This article will also discuss alternative antihypertensive regimens and innovative anesthetic and surgical procedures that have made successful management more promising than ever before. Areas requiring further development include additional clinical experience with the measurement of plasma metanephrines that have been shown to have high sensitivity and specificity in the diagnosis of sporadic and familial pheochromocytoma, optimizing cost effectiveness of diagnostic imaging, improving the ability to predict and treat malignant pheochromocytoma, and elucidating not only the surgical approach but, perhaps with rapid advances in molecular genetics, ways of preventing familial pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920154     DOI: 10.1210/er.2002-0013

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  105 in total

1.  False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.

Authors:  Jay S Fonte; Jeremyjones F Robles; Clara C Chen; James Reynolds; Millie Whatley; Alexander Ling; Leilani B Mercado-Asis; Karen T Adams; Victoria Martucci; Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

2.  Integrative epigenomic and genomic analysis of malignant pheochromocytoma.

Authors:  Johanna Sandgren; Robin Andersson; Alvaro Rada-Iglesias; Stefan Enroth; Goran Akerstrom; Jan P Dumanski; Jan Komorowski; Gunnar Westin; Claes Wadelius
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

Review 3.  Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.

Authors:  Thamara E Osinga; Thera P Links; Robin P F Dullaart; Karel Pacak; Anouk N A van der Horst-Schrivers; Michiel N Kerstens; Ido P Kema
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

Review 4.  Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications.

Authors:  Agata Buonacera; Benedetta Stancanelli; Lorenzo Malatino
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-04-12

5.  Improvement of preoperative management in patients with adrenal pheochromocytoma.

Authors:  Jiang Li; Chang-Hai Yang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

6.  Detecting pheochromocytoma: defining the most sensitive test.

Authors:  Ulrich Guller; Joe Turek; Steve Eubanks; Elizabeth R Delong; Daniel Oertli; Jerome M Feldman
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

7.  Functional paraganglioma.

Authors:  Gokulakrishnan Balasubramanian; Vallikantha Nellaiappan
Journal:  BMJ Case Rep       Date:  2014-02-20

8.  Pheochromocytoma revealed by acute heart failure. When should we operate? Presented at the ESES Congress, Gothenburg May 25-26, 2012.

Authors:  G Müller; F Saint; A Hamy; J C Lifante; B Carnaille; F Sebag; F Ménégaux; J Vandwalle; D Drui; C Caillard; P Rodien; M Roy; J L Peix; F Pattou; L Brunaud; J F Henry; E Mirallié
Journal:  Langenbecks Arch Surg       Date:  2012-12-19       Impact factor: 3.445

9.  A sporadic case of paraganglioma undetected by urine metabolite screening.

Authors:  Detlef Bockenhauer; Lesley Rees; Hartmut Neumann; Ying Foo
Journal:  Pediatr Nephrol       Date:  2008-05-06       Impact factor: 3.714

Review 10.  Update on pediatric pheochromocytoma.

Authors:  Bas Havekes; Johannes A Romijn; Graeme Eisenhofer; Karen Adams; Karel Pacak
Journal:  Pediatr Nephrol       Date:  2008-06-20       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.